Abstract-Vascular aging, as assessed by structural and functional arterial properties, is an independent predictor of cardiovascular risk. We hypothesized that the number of cardiovascular risk factors determines the progression of vascular aging. One hundred forty-two subjects (mean age 51.9 years, 94 men) without established cardiovascular disease were investigated in 2 examinations over a 2-year period. Subjects were classified at baseline according to their number of risk factors (from 0 to 2 and more). Subjects had determinations of carotid-femoral pulse wave velocity, aortic augmentation index, brachial flow-mediated dilatation, and common carotid intima-media thickness and their annual absolute changes were calculated. Subjects with more risk factors had a gradual higher annual progression of pulse wave velocity (0.092 m/s/y for 0, 0.152 m/s/y for 1, and 0.352 m/s/y for 2 and more; P=0.007). Patients with both hypertension and dyslipidemia have 4× higher annual progression rate compared with subjects without these risk factors (0.398 m/s/y versus 0.102 m/s/y). When only subjects 55 years old and under were considered, the progression rate of augmentation index was higher in subjects with more risk factors (1.15%/y versus 1.50%/y versus 2.99%/y, respectively; P=0.037). No association was found with the annual change of flow-mediated dilatation or carotid intima-media thickness. In the general population, increasing number of risk factors is associated with accelerated deterioration of specific indices of vascular aging, such as pulse wave velocity and augmentation index; in contrast, flow-mediated dilatation and carotid intima-media thickness are insensitive to such changes. Accordingly, the former may be more useful for gauging vascular aging. 
D
uring the past decades, a persistent effort has been applied to characterize the effects of aging in several diseases. Undoubtedly, aging is a common, and in most cases, the strongest denominator in the progression of cardiovascular diseases. This notion was colorfully illustrated and described by Dzau et al 1 with the term cardiovascular continuum that explains the gradual development of coronary disease with its complications, which finally lead to heart failure. However, besides the principally atherosclerosis-driven cardiovascular continuum, it must be stressed that an alternative and complementary pattern of development of cardiovascular diseases can be described in cases that the main determinant of disease progression is arteriosclerosis. This was described as the vascular aging continuum that comprehensively encompasses stepwise changes in vascular function and structure and is founded on the inevitable process of aging. 2 Aging of the aorta and elastic arteries causes arterial stiffening and leads to development of cardiac failure and microvascular disease in highly perfused organs, such as the brain and kidneys. Vascular aging continuum provides a more comprehensive explanation, especially for vascular diseases in nations with little atherosclerosis, and has arteriosclerosis (morphological changes in the arterial media layer) as a principal pathophysiological element that influences structural (carotid intima-media thickness [cIMT] ) and functional (arterial stiffening, wave reflections, endothelial dysfunction) arterial indices. Arteriosclerosis contrasts with atherosclerosis that primarily develops in the intimal layer, it is the major cause of atherothrombotic events, and its effect on the aforementioned indexes is variable. With chronological aging, elements of arteriosclerosis and atherosclerosis are interweaved leading to a synergy that augments cardiovascular risk.
Vascular function and early structural alteration are biomarkers of cardiovascular disease and independent predictors of the corresponding risk. 3 Specifically, carotid-femoral pulse wave velocity (cfPWV, aortic stiffness), aortic augmentation index corrected for heart rate of 75 beats per minute (AIx@75, wave reflections), brachial flow-mediated dilatation (FMD, endothelial function), and cIMT (subclinical atherosclerosis) are biomarkers of vascular function and structure that have an essential prognostic role for cardiovascular disease and are considered as markers of subclinical organ damage in hypertension, dyslipidemia, and diabetes mellitus. 3 Vascular age, as assessed by the aforementioned biomarkers, is a promising concept in the quest for the ideal cardiovascular biomarker and can integrate the overall effects through time of both known, as well as unknown, cardiovascular risk factors (RFs). 4 The effect of age and sex is unique on the progression rate of each vascular biomarker. 4 For this reason, it is important to investigate the changes of these biomarkers longitudinally according to the cardiovascular risk profile, 5 as expressed by the number or the certain type of traditional cardiovascular RFs. To this end, we embraced a global approach that included aortic stiffness, wave reflection indices, endothelial function, and carotid artery structure to determine the possible effect of cardiovascular RFs on the annual progression of vascular aging.
Methods

Study Population
Our study population consisted of 142 consecutive subjects (mean age 51.9±10.8 years) enrolled and prospectively followed in the Hypertension and Peripheral Vessels Unit. The study included patients between 25 and 75 years of age that could return for a follow-up visit in 2 years and that remained well controlled regarding their cardiovascular RFs according to the recommendations of the European Society of Cardiology Guidelines. 6 The appropriate treatment was administered whenever needed and this treatment had been initiated for at least a year before the inclusion in the study and did not change in regimen or in dose during the study. All participants were screened for sociodemographic data and RFs for cardiovascular disease and were comprehensively evaluated with a medical history, physical examination, and ECG. Subjects with a history of coronary heart disease, stroke or peripheral artery disease, heart failure, hepatic or renal failure, severe valvular disease, unstable arrhythmia, acute inflammatory diseases, venous thromboembolic disease, autoimmune diseases, or malignant neoplasms were excluded.
Diagnosis of essential hypertension was set if systolic blood pressure (BP) was ≥140 mm Hg or diastolic BP≥90 mm Hg, or if subjects were on treatment with BP-lowering drugs. Diagnosis of dyslipidemia was set if total cholesterol level was ≥190 mg/dL or low-density lipoprotein cholesterol level was ≥115 mg/dL, or if subjects were on treatment with lipid-lowering drugs. Diagnosis of diabetes mellitus was set if plasma glucose level was ≥126 mg/dL (fasting), ≥200 mg/ dL (2 hours after a 75 mg oral glucose load) or glycohemoglobin ≥6.5%, or if subjects were on treatment with antidiabetic drugs. Subjects were categorized as never smokers, past smokers (if they did not smoke for at least a year), and current smokers (if they smoked at least 1 cigarette per day or they quitted smoking during the last year). Metabolic syndrome was defined by the Adult Treatment Panel III criteria. Ethics Committee; all subjects gave written informed consent and the procedures followed were in accordance with institutional guidelines.
Study Design
Measurements of vascular biomarkers were conducted at baseline and at ≈2 years follow-up in a dedicated laboratory with good repeatability of measurements (see also Methods for repeatability estimates in the online-only Data Supplement). All measurements were performed by the same examiner (D.T.P.) throughout the study, who was blinded to the details of individual patients. In both occasions, subjects had fasted and abstained from smoking, caffeine, ethanol, and flavonoid-containing beverages intake for at least 6 hours before each session. All vascular studies were performed in the morning between 8:00 and 10:00 am, in a quiet, temperature-controlled room at 23°C. 8 After a 10-minute rest period, measurements for evaluation of aortic stiffness, wave reflections, endothelial function of the brachial artery, and carotid wall thickness were taken in the supine position, in this fixed order. At the completion of vascular studies, blood was drawn, plasma or serum was separated by centrifugation, and stored at −70°C.
Evaluation of Aortic Stiffness
cfPWV, an established index of aortic stiffness, was calculated from measurements of pulse transit time and the distance travelled between 2 recording sites (PWV equals distance in meters divided by transit time in seconds) with a validated noninvasive device (Complior, Artech Medical, Paris, France). 8 Two different pulse waves were obtained simultaneously at 2 sites (at the base of the neck for the common carotid and over the right femoral artery) with 2 transducers. Distance was defined as the distance from the suprasternal notch to the femoral artery minus the distance from the carotid artery to the suprasternal notch.
Measurement of Peripheral BP, Central BP, and Wave Reflection Indices
Peripheral (brachial) BPs were measured with the Omron M3 Intellisense (Omron healthcare, Kyoto, Japan), an automated and oscillometric upper arm device. Central (aortic) pressures and AIx@75, a composite, indirect index of wave reflections and aortic stiffness, were calculated using a validated, 9 commercially available system (SphygmoCor, AtCor Medical, Sydney, Australia), which uses the principle of applanation tonometry. (See also Methods and Table S1 in the online-only Data Supplement).
Carotid Wall Thickness Measurement
IMT of the right and the left common carotid arteries was measured in the 1-cm segment proximally to the carotid dilation with B-mode ultrasonography, by using a high-resolution, linear-array ultrasonic transducer of 7.5 to 10.5 MHz (Sonos 5500, Hewlett-Packard, Andover, MA). For each patient, mean common cIMT was calculated as the average of 6 measurements of the IMT in the far wall (3 in the right and 3 in the left common carotid artery).
Evaluation of Endothelial Function
FMD of the brachial artery is dependent on endothelial nitric oxide release and can be used as an estimate of endothelial function. FMD was determined as previously described, 10 by using the same ultrasonic transducer and device as described for the carotid imaging. FMD was calculated as the percent change of brachial artery diameter from baseline: FMD (%)=[(postocclusion diameter−resting diameter)/resting diameter]×100.
Laboratory Determinations
High-sensitivity C-reactive protein was measured by immunonephelometry (Dade Behring, Marburg, Germany). Biochemical variables were measured using standard techniques. Estimated glomerular filtration rate was estimated using the Cockcroft-Gault formula.
Statistical Analysis
Subjects were classified at baseline according to their number of cardiovascular RFs in 3 groups. We included the traditional cardiovascular RFs hypertension, dyslipidemia, smoking (including current smokers), and diabetes mellitus that are mainly used in cardiovascular risk prediction scores. The first group had no cardiovascular RFs, the second had 1 cardiovascular RF, and the third group had at least 2 cardiovascular RFs. (See also Methods for power analysis in the online-only Data Supplement).
Continuous variables are expressed as the mean value±SD. Normality of distributions was tested using the KolmogorovSmirnov criterion. Logarithmic transformation was performed for distributions that were significantly skewed before analysis. Skewed variables had a remarkably good fit to normal distribution after log transformation, and they are expressed as a median value (25th-75th percentile).
The role of age in AIx@75 progression was also evaluated when age was considered as a categorical variable. For the purpose of this analysis, subjects were divided into 2 age groups (≤55 and >55 years) based on previous studies that have shown a different progression rate over and below the decade of 50s.
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Changes in the population from the baseline to follow-up were evaluated with paired t test or Wilcoxon signed-rank test. For continuous variables, between-group comparisons were done by using 1-way analysis of variance. For categorical or noncontinuous variables, between-group comparisons were done by the χ 2 test or Kruskal-Wallis rank tests. Linear correlations were evaluated by calculation of the Pearson correlation coefficient. Multivariable analysis was performed by using either analysis of covariance or linear multiple regression analysis and logistic regression analysis, as appropriate. In analysis of covariance, age, sex, and variables that were statistically significant for each vascular biomarker in a multivariable regression analysis were incorporated into the models as confounders (See also Methods and Table S2 ). Exact P values <0.05 were considered statistically significant. Data analysis was performed with SPSS software, version 20 (Chicago, IL).
Results
Vascular Biomarkers and Subject Baseline Characteristics
The characteristics of the study population divided into groups according to the number of RFs are shown in Tables 1 through  3 (see also Tables S3, S4 ). The frequency of subjects without RFs (hypertension, diabetes mellitus, dyslipidemia, and smoking) and subjects with 1, or ≥2 RFs were 49 (34.5%), 52 (36.6%), and 41 (28.9%), respectively. All vascular biomarkers were significantly worse in subjects with more RFs at baseline (Table 3) .
Progression Rate of Vascular Biomarkers in the Prospective Study
During the 2 years of follow-up, all vascular biomarkers showed a significant deterioration in the overall population (Table 1) . Specifically, cfPWV increased by 0.34 m/s, AIx@75 increased by 2.7%, FMD decreased by 0.4%, and cIMT increased by 0.02 mm. On the contrary, both peripheral and aortic BPs and as well as heart rate were not significantly changed.
During follow-up, the unadjusted mean annual change of cfPWV was 0.189 m/s/y (95% confidence interval [CI], 0.122-0.257), of ΑΙx@75 was 1.43%/y (95% CI, 1.03-1.84), of FMD was −0.21%/y (95% CI, −0.39 to −0.03), and of cIMT was 0.017 mm/y (95% CI, 0.014-0.021). Categorical variables are presented as absolute and relative frequencies, while continuous variables as mean value±SD for normally distributed and median value (25th-75th percentile) for skewed variables. P values were obtained by paired t test or Wilcoxon signed-rank test. AIx@75 indicates augmentation index adjusted for heart rate 75 beats per minute; BMI, body mass index; cfPWV, carotid-femoral pulse wave velocity; cIMT, carotid intima-media thickness; eGFR, estimated glomerular filtration rate; FMD, flow-mediated dilatation; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; and LDL, low-density lipoprotein. November 2017 Figure 1 ). Annual progression between groups of AIx@75 (0.96%/y for no RF, 1.57%/y for 1 RF, and 1.83%/y for more than 2 RFs; P=0.245) was not statistically significant. However, when only subjects ≤55 years were considered, the Categorical variables are presented as absolute and relative frequencies, while continuous variables as mean value±SD for normally distributed and median value (25th-75th percentile) for skewed variables. P values were obtained by 1-way analysis of variance, the χ 2 test, or Kruskal-Wallis rank tests across the tertiles. AIx@75 indicates augmentation index adjusted for heart rate 75 beats per minute; cfPWV, carotid-femoral pulse wave velocity; cIMT, carotid intima-media thickness; and FMD, flow-mediated dilatation.
Progression Rate of Vascular Biomarkers and Number of RFs
adjusted progression rate of was significantly higher in subjects with more RFs (1.15%/y versus 1.50%/y versus 2.99%/y, respectively; P=0.037; Figure 2 ). Subjects with more RFs did not show an association with a gradual higher annual deterioration of FMD (−0.14%/y for no RF, −0.14%/y for 1 RF, and −0.39%/y for more than 2 RFs; P=0.495) or cIMT (0.018 mm/y for no RF, 0.015 mm/y for 1 RF, and 0.02 mm/y for more than 2 RFs; P=0.596).
We also investigated the effect of each RF separately on the annual change rate of vascular biomarkers. Subjects with hypertension had a gradual higher annual progression of cfPWV compared with subjects without hypertension (0. Subjects with hypertension had no difference in the annual progression of AIx@75 compared with subjects without hypertension (1.31%/y versus 1.60%/y; P=0.521). When only subjects ≤55 years were considered, there was no difference in the annual progression of AIx@75 compared with subjects without hypertension (2.14%/y versus 1.46%/y; P=0.273). Subjects with dyslipidemia had a gradual higher annual progression of AIx@75 compared with subjects without dyslipidemia only when subjects ≤55 years were considered (2.87%/y versus 1.26%/y, P=0.005, partial η 2 =9.7%). Smokers and diabetics had no differences in the annual progression of AIx@75 compared with nonsmokers (P=0.494) or nondiabetics (P=0.922), respectively.
We observed no effect of each RF separately on the annual change rate of neither FMD nor cIMT. Furthermore, family history of coronary heart disease, baseline renal function, or past smoking were not independent predictors of the annual change rate in any of the vascular biomarkers.
Discussion
To the best of our knowledge, the present study is the first to prospectively investigate in a global approach the Figure 1 . Adjusted mean annual change of carotid-femoral pulse wave velocity (cfPWV) according to the number of vascular risk factors. P value by analysis of covariance. The model was adjusted for age, sex, baseline cfPWV, baseline waist, and annual change in mean blood pressure, in heart rate, in estimated glomerular filtration rate, in uric acid, in white blood cells count, and in high-density lipoprotein. Adjusted mean annual change of carotid-femoral pulse wave velocity (cfPWV) according to the presence of hypertension and dyslipidemia. P value by analysis of covariance. The model was adjusted for age, sex, baseline cfPWV, baseline waist and annual change in mean blood pressure, in heart rate, in estimated glomerular filtration rate, in uric acid, in white blood cells count and in high-density lipoprotein. DPL indicates dyslipidemia; and HTN, hypertension.
relationship between aging and functional and early structural arterial changes as defined by aortic stiffness, wave reflections, conduit artery endothelial function, and IMT of the carotid artery. Importantly, it is the first prospective study that investigated subjects that were well controlled regarding their RFs and on the same background therapy during the whole study follow-up. Confirming our initial hypothesis, the existence of multiple classical cardiovascular RFs imposes a detrimental effect on particular vascular biomarkers prospectively. Specifically, we observed an association between the number of cardiovascular factors and the annual progression rate of cfPWV, as well as of AIx@75 in subjects below the age of 55. However, we did not observe such an impact on FMD and cIMT.
Clinical Implications
The most important implication of our study is that it identifies biomarkers of vascular aging that can serve as surrogate end points and possible therapeutic targets. Specifically, cfPWV and AIx@75 have the ability to change over time and by the effect of traditional RFs/diseases so they are considered practical for clinical integration. The remainder (FMD and cIMT) are either not truly affected (at least during this time span) or they have inherent, methodological limitations to express the effect of aging or RFs; in either case, they are impractical for clinical integration.
Regarding practical aspects of integration of aortic stiffness and wave reflections indexes, we gauged their annual change (without the impact of RFs): this value has to be accounted for when the patient is serially followed-up with this biomarker to dissect normal aging from accelerated one. Further, we provide specific insights on each biomarker. Regarding cfPWV, not only hypertension or BP, but also the less appreciated dyslipidemia proved to have an impact. Together with the synergistic effect of these 2 factors, these findings fit with the concept of a global impact of various RFs on cardiovascular risk. 12 Another important insight should be further stressed. RFs were well controlled by effective contemporary background therapy during the study and change of biomarkers was unrelated to this control. This reinforces the core value of a surrogate end-point according to which it should integrate the effects of a RF or disease that are not confined to the information imparted by the measurement of a specific parameter (ie, level of BP for hypertension, or LDL for dyslipidemia). Furthermore, this may imply that controlling a RF may not completely abrogate its detrimental effects. Undoubtedly, a challenge for future investigation is to unravel the possible difference on the impact of a strict versus less strict control of the respective RF.
Vascular Aging and Cardiovascular RFs: Specific Comments
cfPWV is a powerful predictor of cardiovascular events and overall mortality. 13, 14 Our findings are in accordance with an essential study in France 15 that showed that subjects without hypertension had an annual progression rate of cfPWV at 0.081 m/s/y. Further, in accordance to previous studies, 15, 16 patients with hypertension have a higher annual progression rate of cfPWV that in our study was almost 3× higher. Dyslipidemia is occasionally disregarded as an important determinant of aortic stiffness. 17 However, we showed that patients with dyslipidemia had 2× higher annual progression rate of cfPWV. Of special note is the synergistic effect (4× higher) of the presence of both hypertension and dyslipidemia on the progression of aortic stiffening.
Increased values of AIx@75 have been associated with target organ damage in hypertension and prognosis of future events. 18 The age-specific association of the number of cardiovascular RFs with the annual progression rate of AIx@75 is consistent with the well-established finding that during the 50s, there is a deceleration of the increase rate of AIx@75 11 ; therefore, it seems rational that beyond that period, the effect of RFs in the annual change rate of the biomarker might be negligible. Further, recent large studies support the association of lipid profile with AIx@75 and especially in younger ages, an association that declines with age. 19, 20 The lack of association between RFs and progression rate over 55 might be attributed to the attenuation of the effect of RFs on AIx over 60 years, 19 to the minimal change of AIx beyond the age of 60 years, and to a possible ceiling effect on AIx (as also seen in arterial stiffness) implying that there is no space for further worsening when the baseline level is already high as in patients with 2 or more RFs.
There was no association between the number of cardiovascular RFs and the progression rate of FMD. Although, there is a wealth of data, mostly cross-sectional, showing an association of endothelial function with RFs, 21, 22 these observations have been challenged by recent large studies 23 and the use of FMD as a potential cardiovascular biomarker has been downgraded because of inherent limitations, such as low reproducibility, limited predictive ability and cost. 3 No changes were observed with cIMT over time. Although there are long-term studies that support that RF profile in adolescents predicts adult cIMT, 24 we did not observe such an association in our study population. This could be explained by the relatively short follow-up period that might not have been sufficient to lead to significant changes in cIMT.
Strengths and Limitations
The major strength of our study is that it included patients that did not change their therapeutic regimen during follow-up and had been on stable background therapy for at least a year before their enrollment in the study. Therefore, any short-or medium-term effect of vasoactive substances was avoided. Treatment was managed by the attending physician of each subject. This reflects everyday clinical practice but also incorporates the undiluted by pharmacological treatment effect of aging on vascular biomarkers.
A limitation of our study could be the relatively small sample size both in the overall population and in each RF separately, especially in diabetes mellitus and smoking. Accordingly, there is a theoretical possibility of a type II error that could lead to an inability to detect the possible contribution of the RFs in the annual change rate of vascular biomarkers. However, a detailed, a priori power analysis was conducted to ensure that the cumulative effect of RFs on the progression of cfPWV could be sufficiently investigated.
Perspectives
The present study described a close association between cardiovascular RFs and progression of specific biomarkers of vascular function, demonstrating the accelerated change of these biomarkers when more RFs are present. Importantly, change is irrespective of good control of RFs. Vascular biomarkers such as cfPWV and AIx@75 are more appealing than cIMT and FMD for incorporation in studies as surrogate end points. Furthermore, the impact of these changes of vascular biomarkers with time on future cardiovascular events remains to be investigated. In addition, the possible means for decelerating, halting, or even reversing them as well the effect on cardiovascular events, above and beyond management of classical RFs, poses an enthralling scientific conundrum. Finally, our study stresses the importance of vascular age both in the initial assessment of cardiovascular risk and in the monitoring of cardiovascular risk with time.
Sources of Funding
D. Terentes-Printzios was supported by a Bodossaki Foundation postgraduate scholarship.
Disclosures
None.
